Press Release

Media Contact
Matthias Link
T +49 6172 609-2872
matthias.link@fresenius.com
Contact for analysts andinvestors
Dr. Dominik Heger
T +49 6172 609-2601
dominik.heger@fmc-ag.com
www.freseniusmedicalcare.com

July 16, 2018

Fresenius Medical Care Ventures invests in Israeli medical devicecompany
Fresenius Medical Care Ventures, the venture capital unit of Fresenius Medical Care,announced today that it has invested $2 million in the Series B financing round for
Vectorious Medical Technologies (“Vectorious”). The Israeli medical device company
raised more than $10 million in this financing round, including a recent grant from theEuropean Union’s Horizon 2020 flagship research and development program.
Vectorious has developed the V-LAP, a first of its kind in-heart microcomputer for leftatrial pressure monitoring. Data from this device is transmitted wirelessly to clinicians,
enabling heart failure patients to be managed effectively before their disease advances.
The Series B financing will accelerate Vectorious’ ongoing R&D programs, as well as CE
Mark and FDA regulatory approval initiatives.
“This first investment we have made outside of the United States demonstrates ourconfidence in the great innovative potential for medical products in Israel. Based on thepioneering nature of Vectorious’ technology for managing chronic heart failure patients’care, we see this as a compelling early stage investment opportunity with tremendous
potential,” said Florian Jehle, Managing Director of Fresenius Medical Care Ventures andSenior Vice President Global R&D at Fresenius Medical Care.

Page 1/2About Fresenius Medical Care Ventures GmbH
Fresenius Medical Care Ventures was established in 2016 to invest in start-ups and earlystage companies in the healthcare sector. Its investments are targeted to support
Fresenius Medical Care’s corporate strategy of growing continuously in the company’score dialysis business, expanding into new business areas and improving the health of all
Fresenius patients. Fresenius Medical Care Ventures complements other corporate
innovation initiatives by focusing on early-stage external innovation. For more
information, visit www.fmcv.com.

About Vectorious Medical Technologies
Vectorious Medical Technologies has developed an implantable microcomputer-based
system that enables optimal management of heart failure patients using direct, daily leftatrial pressure (LAP) measurements. The system’s technological infrastructure is basedon use of the first and only sensory implant in the world that is miniature, battery-lessand wireless, and that can communicate accurate readings from the heart. The company
was founded in 2011 at the RadBioMed incubator by Oren Goldshtein, Dr. Eyal Orion andRoni Weinstein. Vectorious has 15 employees at its offices in Ramat Hahayal in Tel Aviv
and at the Cleveland Clinic.

Fresenius Medical Care is the world's largest provider of products and services for individuals withrenal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment.
Through its network of 3,790 dialysis clinics, Fresenius Medical Care provides dialysis treatmentsfor 322,253 patients around the globe. Fresenius Medical Care is also the leading provider ofdialysis products such as dialysis machines or dialyzers. Along with its core business, the company
provides related medical services in the field of Care Coordination. Fresenius Medical Care is listedon the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the Company’s website at www.freseniusmedicalcare.com.
Disclaimer
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual
results could differ materially from those described in these forward-looking statements due to certain factors,
including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate
fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These andother risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S.
Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any
responsibility to update the forward-looking statements in this release.

Page 2/2